Trump’s HHS Opposes Teva’s Fight of Drugs Picked for Price Cuts

The Trump administration is backing a Biden-era decision that selected drugs manufactured by Teva Pharmaceuticals Inc. for the second cycle of the Inflation Reduction Act’s drug price negotiation program.

The Centers for Medicare & Medicaid Services followed its guidance when it picked Teva’s medicines used to treat movement disorders—Austedo and Austedo XR—for the Medicare Drug Price Negotiation Program, the health agency said Tuesday in a cross motion for summary judgment filed in the US District Court for the District of Columbia.

“Given the IRA’s instruction that CMS should consider information ‘aggregated across dosage forms and strengths of the drug, including ...